Newbury Pharmaceuticals AB (NEWBRY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Newbury Pharmaceuticals AB (NEWBRY) has a cash flow conversion efficiency ratio of -0.183x as of November 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-6.55 Million ≈ $-704.78K USD) by net assets (Skr35.85 Million ≈ $3.86 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Newbury Pharmaceuticals AB - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Newbury Pharmaceuticals AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read NEWBRY current and long-term liabilities for a breakdown of total debt and financial obligations.
Newbury Pharmaceuticals AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Newbury Pharmaceuticals AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pearl Gull Iron Ltd
AU:PLG
|
-0.128x |
|
Western Gold Exploration Ltd
V:WGLD
|
-0.468x |
|
Urban One
NASDAQ:UONE
|
-0.002x |
|
Compodium International AB
ST:COMPDM
|
0.009x |
|
Maison Solutions Inc
NASDAQ:MSS
|
0.205x |
|
STRIP TINNING HLDG.LS-01
F:VH3
|
N/A |
|
Klondike Silver Corp
V:KS
|
0.001x |
|
Sagardeep Alloys Limited
NSE:SAGARDEEP
|
-0.207x |
Annual Cash Flow Conversion Efficiency for Newbury Pharmaceuticals AB (2021–2024)
The table below shows the annual cash flow conversion efficiency of Newbury Pharmaceuticals AB from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Newbury Pharmaceuticals AB.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-08-31 | Skr51.92 Million ≈ $5.59 Million |
Skr-23.71 Million ≈ $-2.55 Million |
-0.457x | +2.92% |
| 2023-08-31 | Skr49.38 Million ≈ $5.31 Million |
Skr-23.23 Million ≈ $-2.50 Million |
-0.470x | -115.64% |
| 2022-08-31 | Skr68.77 Million ≈ $7.40 Million |
Skr-15.00 Million ≈ $-1.61 Million |
-0.218x | -106.38% |
| 2021-08-31 | Skr38.47 Million ≈ $4.14 Million |
Skr-4.07 Million ≈ $-437.57K |
-0.106x | -- |
About Newbury Pharmaceuticals AB
Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden and the Scandinavian market. It offers oncology, rare diseases, neurology, and other treatment products. Newbury Pharmaceuticals AB (publ) was incorporated in 2020 and is based in Lund, Sweden.